Expanded Indications Approved for UroLift
FDA has approved new indications for the UroLift System (NeoTract), a treatment for benign prostatic hyperplasia that involves placement, via a minimally invasive procedure, of permanent implants that relieve prostatic obstruction and open the urethra.
UroLift is now approved for use in men with an obstructive median lobe and men as young as 45 years. Previously, UroLift was contraindicated in patients with an obstructive median lobe and only approved for men aged 50 years and older. FDA granted the expanded indications based on the results of the MedLift study.